Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Taiwan University Hospital |
---|---|
Information provided by: | National Taiwan University Hospital |
ClinicalTrials.gov Identifier: | NCT00674349 |
Ovarian cancer is the first mortality rate of gynecologic malignancies. The incidence of ovarian cancer increased in recent 10 years and it has become the ninth cause of malignancies in the women in Taiwan. From the above-mentioned data, ovarian cancer indeed is a disease that should be respected, however, there were only few of research work focusing on it in Taiwan. Despite the widespread use of aggressive cytoreductive surgery and the introduction of chemotherapy regimens, the overall survival has changed little over the last two decades. The basic problem in treating epithelial ovarian cancer is that once it has spread beyond the ovary, it is exceedingly difficult to control and ultimately to cure. More than 70% of ovarian cancer patients were advanced stage when diagnosed. To study the mechanisms of carcinogenesis, progression, and metastasis of ovarian cancer will help us understand this disease and develop new treatment strategies for ovarian cancer in the future.
We have established an ascitogenic itnraperitoneal tumor cell line-WF3 in the mouse model in our previous two-year project of NSC grant (grant number (NSC90-2314-B-002-457 and NSC91-2341-B-002-315). Our group found that, mesothelin, this molecule is highly related with the carcinogenesis, tumor progression and tumor metastasis in our animal model and human cancer tissues. To further evaluate the role of mesothelin in ovarian cancer and elucidate the potential of mesothelin as a target antigen for immunotherapy,
Condition | Intervention |
---|---|
Endometrial Cancers |
Procedure: surgery |
Study Type: | Interventional |
Study Design: | Basic Science, Open Label, Uncontrolled, Parallel Assignment |
Official Title: | Screening and Identification of Novel Diagnostic and Prognostic Biomarkers on Endometrial Cancers |
Estimated Enrollment: | 250 |
Study Start Date: | January 2006 |
Estimated Study Completion Date: | December 2011 |
Estimated Primary Completion Date: | January 2007 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 15 Years to 80 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Contact: WEN-FANG CHENG, Associate Professor | 886-2-23123456 | wenfangcheng@yahoo.com |
Taiwan | |
National Taiwan University Hospital | Recruiting |
TAIPEI, Taiwan | |
Contact: WEN-FANG CHENG, ASSOCIATE PROFESSOR 886-2-23123456 wenfangcheng@yahoo.com |
Responsible Party: | National Taiwan Unviersity Hospital ( Wen-Fang Cheng/Associate Professor ) |
Study ID Numbers: | 200706001R |
Study First Received: | May 4, 2008 |
Last Updated: | July 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00674349 History of Changes |
Health Authority: | Taiwan: Department of Health |
Genital Diseases, Female Endometrial Neoplasms Genital Neoplasms, Female Uterine Diseases |
Uterine Neoplasms Endometrial Cancer Urogenital Neoplasms |
Genital Diseases, Female Neoplasms Endometrial Neoplasms Neoplasms by Site |
Genital Neoplasms, Female Uterine Diseases Uterine Neoplasms Urogenital Neoplasms |